{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:39:19Z","timestamp":1794004759718,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.semarthrit.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T14:54:17Z","timestamp":1631804057000},"page":"1200-1204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review"],"prefix":"10.1016","volume":"51","author":[{"given":"Hafiz M","family":"Umair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Alunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2021.09.002_bib0001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud's phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.09.002_bib0002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10067-021-05598-7","article-title":"How do patients define Raynaud's phenomenon? Differences between primary and secondary disease","volume":"40","author":"Murphy","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.09.002_bib0004","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud's phenomenon","volume":"20","author":"Haque","year":"2020","journal-title":"Clin Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.09.002_bib0005","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","article-title":"Raynaud's phenomenon-an update on diagnosis, classification and management","volume":"38","author":"Pauling","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.09.002_bib0006","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.09.002_bib0007","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamadermatol.2021.1463","article-title":"A practical approach to the management of digital ulcers in patients with systemic sclerosis","volume":"157","author":"Hughes","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.09.002_bib0008","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S2215-0366(17)30167-0","article-title":"ADHD in children and young people: prevalence, care pathways, and service provision","volume":"5","author":"Sayal","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.09.002_bib0009","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/mrdd.10036","article-title":"The epidemiology of attention-deficit\/hyperactivity disorder (ADHD): a public health view","volume":"8","author":"Rowland","year":"2002","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.09.002_bib0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/JCP.0000000000001007","article-title":"Methylphenidate-induced Raynaud phenomenon developed after increasing methylphenidate in an adult with attention-deficit hyperactivity disorder","volume":"39","author":"Monteerarat","year":"2019","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.09.002_bib0011","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1358863X18790101","article-title":"Peripheral vascular manifestation in patients receiving an amphetamine analog: a case series","volume":"24","author":"Tan","year":"2019","journal-title":"Vasc Med"},{"key":"10.1016\/j.semarthrit.2021.09.002_bib0012","series-title":"Raynaud's phenomenon","first-page":"141","article-title":"Other secondary causes","author":"Anderson","year":"2015"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.09.002_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/RHU.0b013e3181639aaa","article-title":"Methylphenidate and dextroamphetamine-induced peripheral vasculopathy","volume":"14","author":"Syed","year":"2008","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.09.002_bib0014","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","article-title":"Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors","volume":"31","author":"Gasparyan","year":"2011","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.09.002_bib0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.23301","article-title":"Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients","volume":"58","author":"Goldman","year":"2008","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.09.002_bib0016","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/cap.2012.0131","article-title":"Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl","volume":"23","author":"G\u00f6k\u00e7en","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.09.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102439","article-title":"Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature","volume":"19","author":"Meridor","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.09.002_bib0018","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.17l02240","article-title":"Lisdexamfetamine and secondary Raynaud's phenomenon","volume":"20","author":"Gnanavel","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.09.002_bib0019","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2310\/7750.2014.14052","article-title":"Diseases of abnormal sensitivity to cold in children on psychostimulant drugs","volume":"19","author":"Coulombe","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.semarthrit.2021.09.002_bib0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bcp.12912","article-title":"Drug-induced Raynaud's phenomenon: beyond \u03b2-adrenoceptor blockers","volume":"82","author":"Khouri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.09.002_bib0021","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK scleroderma study group: digital vasculopathy in systemic sclerosis","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.09.002_bib0022","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.semarthrit.2016.05.001","article-title":"Differential diagnosis of critical digital ischemia in systemic sclerosis: report of five cases and review of the literature","volume":"46","author":"Sharp","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.09.002_bib0023","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bjd.19243","article-title":"Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection","volume":"183","author":"Hughes","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.09.002_bib0024","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamadermatol.2020.4324","article-title":"Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic","volume":"157","author":"Hubiche","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.09.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102899","article-title":"Similarities between COVID-19 and systemic sclerosis early vasculopathy: a \u201cviral\u201d challenge for future research in scleroderma","volume":"20","author":"Matucci-Cerinic","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.09.002_bib0026","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/00004583-199608000-00008","article-title":"Attention deficit disorder: a review of the past 10 years","volume":"35","author":"Cantwell","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.semarthrit.2021.09.002_bib0027","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fphar.2016.00438","article-title":"Raynaud's phenomenon: a brief review of the underlying mechanisms","volume":"7","author":"Fardoun","year":"2016","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.09.002_bib0028","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/2397198318774307","article-title":"Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report","volume":"3","author":"Pauling","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.09.002_bib0029","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.semarthrit.2021.04.005","article-title":"Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: report from OMERACT 2021","volume":"51","author":"Maltez","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.09.002_bib0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/cap.2019.0025","article-title":"Raynaud's phenomenon related with atomoxetine treatment in a child with autism and attention-deficit\/hyperactivity disorder","volume":"29","author":"G\u00fclle","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T04:38:41Z","timestamp":1672720721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221001815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0049017221001815"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.09.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}